Exon 18, 19, 20, and 21 mutations are common mutant genotypes in patients with NSCLC, with exon 19 deletions and the L858R point mutation in exon 21 together accounting for approximately 85% of all EGFR mutations in NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.